Abstract:Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are an important parameter of host defenses that limit viral replication after infection. Induction of effective CTL against conserved viral proteins such as Gag may be essential to the development of a safe and effective HIV type 1 (HIV-1) vaccine. DNA vaccination represents a novel strategy for inducing potent CD8(+) CTL responses in vivo. However, expression of HIV-1 structural proteins by DNA vectors has been hampered by a stringent requirement for coexpression with other viral components, such as Rev and RRE. Furthermore, even with Rev and RRE present, the level of expression of HIV-1 Gag, pol, or Env is very low in murine cells. These problems have limited our ability to address the key issue of how to generate effective CTL responses to Gag in a mouse model. To overcome this problem, we compared several novel DNA expression vectors for HIV-1 Gag protein expression in primate and mouse cells and for generating immune responses in mice after DNA vaccination. A DNA vector containing wild type HIV-1 gag coding sequences did not induce detectable Gag expression in any of the cells tested. Attempts to increase nuclear export of Gag expression RNA by adding the constitutive transport element yielded only a moderate increase in Gag expression in monkey-derived COS cells and an even lower increase in Gag expression in HeLa cells or several mouse cell lines. In contrast, silent-site mutations in the HIV-1 gag coding sequences significantly increased Gag expression levels in all cells tested. Furthermore, this construct induced both Gag-specific antibody and CTL responses in mice after DNA vaccination. Using this construct, we achieved stable expression of HIV-1 Gag in the mouse cell line p815, which can now be used as a target cell for measuring HIV-1 Gag-specific CTL responses in immunized mice. The DNA vectors described in this study should make it possible to systematically evaluate the approaches for maximizing the induction of CTL responses against HIV-1 Gag in mouse and other animal systems.

[Construction of the Recombinant Lactococcus Lactis Expressing HIV-1 Gag Protein and Its Colonization in Mice].

Construction of Replication-Deficient Recombinant Adenovirus Expressing Gag-Pola and Gp140tm Genes of Human Immunodeficiency Virus in Mice

Construction and Immunogenicity of Recombinant Modified Vaccinia Ankara Expressing HIV-1 Gag-Pol Antigen

A Mouse Model Based on Replication-Competent Tiantan Vaccinia Expressing Luciferase/Hiv-1 Gag Fusion Protein for the Evaluation of Protective Efficacy of Hiv Vaccine

Evaluation Of Novel Human Immunodeficiency Virus Type 1 Gag Dna Vaccines For Protein Expression In Mammalian Cells And Induction Of Immune Responses

[Expression in Pichia Pastoris, Fermentation and Purification of HIV-1 CN54 Gag Antigen].

Construction and Immunogenicity of HIV-1 DNA Vaccine

Expression and characterization of Gag protein of HIV-1CN in Pichia pastoris

Immunogenicity of Yeast Expressed Chinese HIV-1 Gag Protein (CN54, B'/C Recombinant) in Mice

Expression of HIV-1 Gag Protein in Recombinant Fowlpox Virus

Construction and Immunology of HIV-2 Gp105 and / or Gag DNA Vaccine

Construction and Immunological Study of Recombinant Plasmid with HIV-1 Gag and IFN - Alpha2b

[Study on the Immunogenicity of HIV-1 Gag Vaccine].

[Immune Response Induced by HIV DNA Vaccine Combined with Recombinant Adeno-Associated Virus].

[The Immune Response in Mice Inoculated with HIV-1 Gag-Gp120 Chimeric Gene DNA Vaccine and IL-18 Plasmid].

Engineering Lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin

Construction of Recombinant Fowlpox Virus(Rfpv) Expressing Hiv-1 Gag-Pol Protein

Construction and characterization of a recombinant fowlpox virus containing HIV-1 multi-epitope-p24 chimeric gene in mice

The expression of HIV-1 tat in Lactococcus lactis

Expression of recombinant plasmid of HIV-1 gp120 and IFN-gamma in E. coli and its immunoregulatory effect]

Construction of a Recombinant HIV-1 Gp140 Protein Vaccine and Evaluation of Its Immunogenicity